Scopus Biopharma Inc
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3s… Read more
Scopus Biopharma Inc (SCPS) - Total Liabilities
Latest total liabilities as of June 2023: $11.00 Million USD
Based on the latest financial reports, Scopus Biopharma Inc (SCPS) has total liabilities worth $11.00 Million USD as of June 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Scopus Biopharma Inc - Total Liabilities Trend (2017–2022)
This chart illustrates how Scopus Biopharma Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Scopus Biopharma Inc Competitors by Total Liabilities
The table below lists competitors of Scopus Biopharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
RoboGroup T.E.K. Ltd
PINK:ROBOF
|
USA | $14.06 Million |
|
TAYLOR WIMPEY - Dusseldorf Stock Exchang
DU:TWW
|
Germany | €1.73 Billion |
|
Chykingyoung Investment Development Holdings Inc
PINK:CHYI
|
USA | $5.96 Million |
Liability Composition Analysis (2017–2022)
This chart breaks down Scopus Biopharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 22.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Scopus Biopharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Scopus Biopharma Inc (2017–2022)
The table below shows the annual total liabilities of Scopus Biopharma Inc from 2017 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | $7.45 Million | +78.75% |
| 2021-12-31 | $4.17 Million | +9.59% |
| 2020-12-31 | $3.81 Million | +345.30% |
| 2019-12-31 | $854.54K | +519.39% |
| 2018-12-31 | $137.96K | +23.98% |
| 2017-12-31 | $111.28K | -- |